Search

Tisotumab vedotin

was 8.3 months. … The approval was based on tumour response and the durability of the response as demonstrated in InnovaTV 204 (NCT03438396): in this trial, the objective response rate was 24% and the median response duration

Etofenamate

Etofenamate is used to treat muscle and joint paint. It is a non-steroidal anti-inflammatory drug (NSAID).

Technetium Tc-99m sulfur colloid

This is possible as Technetium-99m decays by isomeric transition to technetium-99 through the release of a gamma ray.

Fenoldopam

A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.

Fruquintinib

-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. … This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791]

Vapreotide

It was being studied for the treatment of cancer.

Chromous sulfate

Eszopiclone

Eszopiclone was initially approved by the FDA in 2004.[L6769] … It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.

Chromium gluconate

Chromium nicotinate